ATG4B and neoplasm: In a stratified survival analysis of ATG4B and pS383/392-ATG4B, there was increased risk of cancer death in CRC patients with early clinicopathological stages, such as AJCC stage I and II and no lymph node invasion (N0), whereas there were no significant effects in patients with well differentiated tumor cells and small tumor sizes (T1 and T2).